missing translation for 'onlineSavingsMsg'
Learn More
  1. Home
  2. Products
  3. Recombinant Proteins
  4. Gibco™ Human IFN-beta Recombinant Protein, PeproTech®

Gibco™ Human IFN-beta Recombinant Protein, PeproTech®

Catalog No. p-7245915
Encompass
Change view
Click to view available options
Quantity:
100 μg
2 x 500 μg
20 μg
250 μg
5 μg
50 μg
500 μg
7 product options available for selection
Product selection table with 7 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
30002BC100 100 μg
30002BC1MG 2 x 500 μg
30002BC20UG 20 μg
30002BC250 250 μg
30002BC500 500 μg
30002BC50UG 50 μg
30002BC5UG 5 μg
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 7 options available.
7 options
Catalog No. 30002BC100 Supplier Gibco™ Supplier No. 30002BC100UG
Only null left

Description

Recombinant Protein

300-02BC-1MG will be provided as 2 x 500 μg (300-02BC-500UG). PeproTech's Recombinant Human IFN-beta is a 20.0 kDa protein containing 166 amino acid residues. Due to glycosylation, IFN-beta has an approximate MW of 22.3 kDa based on SDS-PAGE gel and Mass Spectrometry. *Human IFN-beta (Catalog Number 300-02BC) has replaced Human IFN-beta (Catalog Number 300-02B) This product is shipped at ambient temperature. For storage, handling and reconstitution information, please see the lot-specific Certificate of Analysis

Type I Interferons (IFN-alpha/beta) are produced primarily in response to viral infection by Natural IFN-producing cells (IPCs) as part of the host immune response. IFNs can also inhibit the development of tumors. IFN-beta binding results in the activation of the tyrosine kinases Jak1 and Tyk2, phosphorylation of members of the STAT family of transcription factors, and the transcription and expression of the immune response genes. More recently, several members of the toll-like receptor (TLR) family were found to stimulate the production IFN-beta. IFN-beta is currently used clinically for treatment of tumors, infections and multiple sclerosis.

Specifications

Accession Number P01574
For Use With (Application) Control, Bioactivity
Formulation Protein with no preservative
Gene ID (Entrez) 3456
Molecular Weight (g/mol) 20 kDa
Name Human IFN-beta
Purification Method Purified
Quantity 100 μg
Source CHO cells
Storage Requirements -20°C
Regulatory Status RUO
Endotoxin Concentration <1 EU/μg
Gene Alias Fibroblast interferon; Ifb; IFF; IFN b; IFN β; IFNB; Ifnb1; IFNbeta; IFN-beta; IFNβ; Interferon; Interferon b; Interferon beta; interferon beta 1; interferon beta 1, fibroblast; interferon beta protein; interferon, beta 1; interferon, beta 1, fibroblast; interferon-beta; RP11-113D19.1
Common Name IFN beta
Gene Symbol Ifnb1
Biological Activity Determined by a cytotoxicity assay using human TF-1 cells. The expected ED50 is ≤ 0.1 ng/ml, corresponding to a specific activity of ≥ 1 x 10^7 units/mg
Product Type Protein
Conjugate Unconjugated
Recombinant Recombinant
Sequence MSYNLLGFLQ RSSNFQCQKL LWQLNGRLEY CLKDRMNFDI PEEIKQLQQF QKEDAALTIY EMLQNIFAIF RQDSSSTGWN ETIVENLLAN VYHQINHLKT VLEEKLEKED FTRGKLMSSL HLKRYYGRIL HYLKAKEYSH CAWTIVRVEI LRNFYFINRL TGYLRN
Content And Storage -20°C
Activity Determined by a cytotoxicity assay using human TF-1 cells. The expected ED50 is ≤ 0.1 ng/ml, corresponding to a specific activity of ≥ 1 x 10^7 units/mg.
Expression System CHO cells
Form Lyophilized
Purity or Quality Grade ≥ 95% by SDS-PAGE gel and HPLC analyses.
Show More Show Less